← Back to Search

Cancer Vaccine

Pneumonia Vaccine for People with HIV (VIVID Trial)

Phase 4
Recruiting
Research Sponsored by Hennepin Healthcare Research Institute
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 30 days and 2 years
Awards & highlights

Summary

This trial will monitor how well a pneumonia vaccine works over time in people with HIV and how age affects its effectiveness.

Who is the study for?
This trial is for aging individuals living with HIV. It's designed to understand how well and for how long a pneumococcal vaccine (PCV20) can protect them against infections.
What is being tested?
The study focuses on the immune response to the PCV20 vaccine in people with HIV as they age, tracking how effective the vaccine is over time in providing protection.
What are the potential side effects?
Possible side effects of PCV20 may include pain at injection site, fatigue, headache, muscle pain, joint pain, decreased appetite, chills or rash.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~30 days and 2 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 30 days and 2 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Primary objective
Secondary study objectives
Secondary objective

Trial Design

1Treatment groups
Experimental Treatment
Group I: Pneumococcal VaccinationExperimental Treatment1 Intervention
All participants will receive a pneumococcal vaccine.

Find a Location

Who is running the clinical trial?

Hennepin Healthcare Research InstituteLead Sponsor
91 Previous Clinical Trials
77,177 Total Patients Enrolled
~167 spots leftby Dec 2029